Neumora Therapeutics (NMRA) Shares Outstanding (Diluted Average) (2022 - 2026)

Neumora Therapeutics has reported Shares Outstanding (Diluted Average) for 5 years, with the latest figure at $179.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 11.41% year-over-year to $179.9 million; the trailing twelve-month figure through Mar 2026 stood at $179.9 million (up 11.41% YoY), and the FY2025 full-year result was $163.4 million, up 2.52% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $179.9 million, up from $163.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $179.9 million in Q1 2026, with the low at $27.2 million in Q4 2022.
• Average Shares Outstanding (Diluted Average) over 5 years is $112.6 million, with a median of $158.8 million recorded in 2024.
• Year-over-year, Shares Outstanding (Diluted Average) soared 439.48% in 2024 and grew 1.7% in 2025.
• Tracing NMRA's Shares Outstanding (Diluted Average) over 5 years: stood at $27.2 million in 2022, then jumped by 138.99% to $65.0 million in 2023, then jumped by 145.12% to $159.4 million in 2024, then increased by 2.52% to $163.4 million in 2025, then climbed by 10.09% to $179.9 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $179.9 million (Q1 2026), $163.4 million (Q4 2025), and $161.7 million (Q3 2025), per Business Quant data.

Peer Comparison